LL
LLY
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Ken Fisher | Fisher Asset Management | $6,073M | 1.8% | 2026-06-30 |
| Saturna Capital | Amana Mutual Funds Trust | $539M | 6.6% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $104M | 0.4% | 2026-06-30 |
| Dodge & Cox | Dodge & Cox | $49M | 0.0% | 2026-06-30 |
| Wahed Invest | Wahed Invest LLC | $23M | 2.4% | 2026-06-30 |
| Stanley Druckenmiller | Duquesne Family Office | $15M | 0.3% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $7M | 0.6% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Lilly(Eli) & Co (LLY) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for LLY — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 36.90 | NEUTRAL |
| Stochastic %K (14) | 5.99 | BUY |
| CCI (20) | -111.27 | BUY |
| Williams %R (14) | -94.01 | BUY |
| MACD (12,26,9) | -10.43 | SELL |
| ROC (10) | -5.58 | SELL |
| Momentum (10) | -66.41 | SELL |
| EMA (10) | 1151.71 | SELL |
| SMA (10) | 1150.76 | SELL |
| EMA (20) | 1169.39 | SELL |
| SMA (20) | 1187.70 | SELL |
| EMA (30) | 1173.75 | SELL |
| SMA (30) | 1183.09 | SELL |
| EMA (50) | 1165.90 | SELL |
| SMA (50) | 1185.12 | SELL |
| EMA (100) | 1125.07 | SELL |
| SMA (100) | 1113.14 | BUY |
| EMA (200) | 1058.32 | BUY |
| SMA (200) | 1061.69 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Lilly(Eli) & Co
Healthcare · Drug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Background via Yahoo Finance — informational, not part of the verdict.
🔴 AVOID
The main driver: lagging the market by 5.3%, insider selling on the open market. Too many signals pointing the wrong way. Wait for the picture to improve before committing capital.
Scores: 1 bullish / 3 bearish
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | BEARISH | 62 |
| ⏰ 4H | RANGING | 57 |
| 🕐 1H | BULLISH | 98 |
| ⏱ 15-Min | BEARISH | 130 |
| ⏲ 5-Min | RANGING | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
BEARISH 0 buys · 2 sells
Recent: Hakim Anat sold 11875 sh @ $1190.00 (2026-08-07); Zakrowski Donald A sold 1526 sh @ $1185.01 (2026-08-10)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.